The COVID-19, an acute respiratory syndrome caused by SARS-CoV2 is a major catastrophic event of the twenty first century. Relentless efforts for the development of effective pharmaco-therapeutics are in progress but the respite is the development of effective vaccines. However, monotherapy might not always exhibit complete efficacy and may culminate in the rapid evolution of drug-resistant viral strains. Hence, simultaneous modulation of multiple druggable targets not only enhances therapeutic efficacy but also quell the prospects of mutant viruses. Currently, milk peptides have bloomed beyond just being a quintessential part of nutrition to prominent therapeutic implications in human health and diseases. Hence, we have focused on colostrum/milk peptides as they have already been acknowledged for their high potency, target specificity with significantly low or no side effects and bio-toleration. The results presented provide a conceptual strategy for the rational designing of prospective multitargeted peptide inhibitors for SARS-CoV2.

COVID-19 是一种由 SARS-CoV2 引起的急性呼吸系统综合症，是 21 世纪的重大灾难性事件。开发有效药物治疗的不懈努力正在进行中，但有效疫苗的开发是暂时的。然而，单一疗法可能并不总是表现出完全的疗效，并可能最终导致耐药病毒株的快速进化。因此，同时调节多个可药用靶标不仅可以提高治疗效果，还可以平息突变病毒的前景。目前，牛奶肽已不仅仅只是营养的典型组成部分，还对人类健康和疾病具有显着的治疗意义。因此，我们专注于初乳/牛奶肽，因为它们的高效力已经得到认可，具有显着低或无副作用和生物耐受性的靶向特异性。所呈现的结果为合理设计针对 SARS-CoV2 的前瞻性多靶点肽抑制剂提供了概念性策略。